[1] Durski JM, Weigel RJ, Mcdougall IR, et al.Recom-binant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer[J].Nucl Med Commun, 2000, 21(6):521-528.
[2] Meier CA, Braverman LE, Ebner SA, et al.Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study)[J].J Clin Endocrinol Metab, 1994, 78(1):188-196.
[3] Haugen BR, Pacini F, Reiners C, et al.A comparison of recombinant human thyrotropin and thyroid hor-mone withdrawal for the detection of thyroid remnant or cancer[J].J Clin Endocrinol Metab, 1999, 84(11):3877-3885.
[4] Ladenson PW, Braverman LE, Mazzaferri EL, et al.Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma[J].N Engl J Med, 1997, 337(13):888-896.
[5] Maruca J, Santner S, Miller K, et al.Prolongedio-dine clearance with a depletion regimen for thyroid carcinoma:concise comunication[J].J Nucl Med, 1984, 25(10):1089-1093.
[6] Koong SS, Reynolds JC, Movius EG, et al.Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated throid carcinoma[J].J Clin En-docrinol Metab, 1999, 84(3):912-916.
[7] Ang ES, Teh HS, Sundram FX, et al.Effect of lithium and oral thyrotrophin-releasing hormone(TRH) on serum thyrotrophin (TSH) and radioiodine uptake in patients with well differentiated thyroid carcinoma[J].Singapore Med J, 1995, 36(6):606-608.
[8] Pons F, Carrio I, Estorch M, et al.Lithium as an adjuvant of Iodine-131 uptake when wreating patients with well differentiated thyroid carcinoma[J].Clin Nucl Med, 1987, 12(8):644-647.
[9] Grunwald F, Menzel C, Bender H, et al.Redifferentiation therapy-induced radioiodine uptake in thyroid cancer[J].J Nucl Med, 1998, 39(11):1903-1906.
[10] Simon D, Koehrle J, Reiners C, et al.Redifferentiation therapy with retinoids:therapeutic option for advanced follicular and papillary thyroid carcinoma[J].World J Surg, 1998, 22(6):569-574.